Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
HELIUM, USP is an inhaled medical gas approved by FDA in October 2018 for therapeutic use. The product is a simple inert gas with no traditional pharmacologic mechanism of action. It is administered via inhalation route as a gas dosage form.
Product is in peak lifecycle stage with no current Part D spending data reported, suggesting limited commercial momentum or niche market positioning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HELIUM, USP currently shows zero linked job openings, indicating a minimal or stable commercial team supporting a niche product. Career growth on this product is limited unless the company expands indications, addresses safety concerns through regulatory initiatives, or scales commercial infrastructure.